Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erika Rimondi

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Biomolecules|October 23, 2021
Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the InflammationErika Rimondi, Erica Valencic, Alberto Tommasini, et al.
International Journal of Molecular Sciences|February 25, 2023
Mitochondria-Targeted Antioxidants, an Innovative Class of Antioxidant Compounds for Neurodegenerative Diseases: Perspectives and LimitationsMatteo Fields, Annalisa Marcuzzi, Arianna Gonelli, et al.
Journal of Cellular Physiology|October 26, 2005
Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiationErika Rimondi, Paola Secchiero, Andrea Quaroni, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 27, 2007
MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathwayGiorgio Zauli, Erika Rimondi, Federica Corallini, et al.
Hematological Oncology|September 6, 2019
New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advancesCarolina Simioni, Fabio Bergamini, Martina Ferioli, et al.
Investigational New Drugs|December 3, 2010
Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAILArianna Gonelli, Oriano Radillo, Sara Drioli, et al.
International Journal of Molecular Sciences|April 12, 2022
Acute Neurological Involvement after Donor Lymphocyte Infusion for Post-Transplant Viral Infection: The Same Pattern of Novel Cancer Immunotherapy-Related CNS Toxicity?Annalisa Marcuzzi, Erika Rimondi, Elisabetta Melloni, et al.
Frontiers in Medicine|November 17, 2022
The role of the mTOR pathway in diabetic retinopathyFabio Casciano, Enrico Zauli, Erika Rimondi, et al.
Life Science Alliance|March 6, 2023
Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipientsDomenica Squillaci, Annalisa Marcuzzi, Erika Rimondi, et al.
Neoplasia (New York, N.Y.)|December 13, 2003
TRAIL activates a caspase 9/7-dependent pathway in caspase 8/10-defective SK-N-SH neuroblastoma cells with two functional end points: induction of apoptosis and PGE2 releaseGiorgio Zauli, Daniela Milani, Erika Rimondi, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Biomolecules|October 23, 2021
Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the InflammationErika Rimondi, Erica Valencic, Alberto Tommasini, et al.
International Journal of Molecular Sciences|February 25, 2023
Mitochondria-Targeted Antioxidants, an Innovative Class of Antioxidant Compounds for Neurodegenerative Diseases: Perspectives and LimitationsMatteo Fields, Annalisa Marcuzzi, Arianna Gonelli, et al.
Journal of Cellular Physiology|October 26, 2005
Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiationErika Rimondi, Paola Secchiero, Andrea Quaroni, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 27, 2007
MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathwayGiorgio Zauli, Erika Rimondi, Federica Corallini, et al.
Hematological Oncology|September 6, 2019
New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advancesCarolina Simioni, Fabio Bergamini, Martina Ferioli, et al.
Investigational New Drugs|December 3, 2010
Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAILArianna Gonelli, Oriano Radillo, Sara Drioli, et al.
International Journal of Molecular Sciences|April 12, 2022
Acute Neurological Involvement after Donor Lymphocyte Infusion for Post-Transplant Viral Infection: The Same Pattern of Novel Cancer Immunotherapy-Related CNS Toxicity?Annalisa Marcuzzi, Erika Rimondi, Elisabetta Melloni, et al.
Frontiers in Medicine|November 17, 2022
The role of the mTOR pathway in diabetic retinopathyFabio Casciano, Enrico Zauli, Erika Rimondi, et al.
Life Science Alliance|March 6, 2023
Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipientsDomenica Squillaci, Annalisa Marcuzzi, Erika Rimondi, et al.
Neoplasia (New York, N.Y.)|December 13, 2003
TRAIL activates a caspase 9/7-dependent pathway in caspase 8/10-defective SK-N-SH neuroblastoma cells with two functional end points: induction of apoptosis and PGE2 releaseGiorgio Zauli, Daniela Milani, Erika Rimondi, et al.
Pageof 7